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ABSTRACT. This study aims to design an optimal polyelectrolyte multilayer film of poly-L-
lysine (PLL) and hyaluronic acid (HA) as an anti-inflammatory cytokine release system in order 
to decrease the implant failure due to any immune reactions. The chemical modification of the 
HA with aldehyde moieties allows self-crosslinking of the film and an improvement in the 
mechanical properties of the film. The crosslinking of the film and the release of 
immunomodulatory cytokine (IL-4) stimulate the differentiation of primary human monocytes 
seeded on the films into pro-healing macrophages phenotype. This induces the production of 
anti-inflammatory cytokines (IL1-RA and CCL18) and the decrease of pro-inflammatory 
cytokines secreted (IL-12, TNF-α and IL-1β). Moreover, we demonstrate that crosslinking 
PLL/HA film using HA-aldehyde is already effective by itself to limit inflammatory processes. 
Finally, this functionalized self-crosslinked PLL/HA-aldehyde films constitutes an innovative 
and efficient candidate for immunomodulation of any kind of implants of various architecture 
and properties. 
Introduction 
In recent years modification of biomaterial surfaces has been studied through various methods 
to render them bioactive. Surface coatings based on the layer-by-layer (LbL) method have been 
reported as a versatile and easy way of building polymeric surface coatings in environmentally 
friendly conditions, mostly from aqueous solutions.
1
 The layer-by-layer method is based on the 
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electrostatic attraction between polyanions and polycations, the advantage of this method is the 
possibility of preparing ultra-thin and well-defined films.
2, 3
 The spontaneous sequential 
adsorption of dissolved cationic and anionic polyelectrolytes on the substrate leads to the 
formation of ordered multilayer assemblies on the solid substrate surface.
4
 These multilayers are 
widely used in biotechnology as controlled release systems, cell growth surfaces, anti-adhesive 
coatings and stimuli responsive surfaces. As the system is composed of charged molecules, it is  
ideal to control the release of charged bioactive agents such as cytokines and the strength of 
electrostatic interactions between the film and the cytokine should be a key parameter to 
determine the rate of release.
5, 6
 
Biological properties and physicochemical characteristics of polyelectrolyte multilayer film 
coated device surfaces have been explored in order to get better properties between the implant 
and tissue interface.
7
 The polyelectrolyte multilayer films PLL/HA ((poly(L-lysine) associated 
with hyaluronic acid) have been extensively studied. Furthermore, it has been successfully used 
for the release of growth factors and drugs.
8-11
 Degradation of these films via dissolution is an 
obstacle for achieving long-term release of cytokines, which can be improved by structures 
crosslinking.
12, 13
 Moreover, it is known that crosslinking these PLL/HA films strongly increase 
viability of cells growing on the films, mainly due to an increase of Young modulus.
14, 15
 For 
example, the chemical crosslinking with a mixture of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide/N-hydroxysulfosuccinimide (EDC/NHS) is widely used for 
several polyelectrolyte multilayers (PEMs), typically, PLL/HA, PLL/polyglutamic acid 
(PLL/PGA), and chitosan/HA.
16-18
 The EDC/NHS crosslinking involves a reaction between 
carboxylic groups of HA and amine groups of PLL. However, to achieve the crosslinking 
 4 
reaction a long incubation time is required (at least 12 hours) and also some extensive rising 
steps after it, in order to eliminate excess products that can be toxic.
19
 
Hyaluronic acid (HA) is a glycosaminoglycan mainly localized in extracellular matrix. It plays 
an important role in lubrication, cell differentiation, angiogenesis, anti-inflammatory response 
and cell growth. Since HA plays a major role in all wound healing steps, its exogenous 
application presents the potential to get a faster healing. The presence of the functional groups 
such as alcohols and carboxylic acids along the backbone of HA allows the introduction of  
functional domains on it.
20, 21
 The addition of functional groups provides the possibility to adjust 
physical parameters of the films formed with the HA and consequently the cell response to these 
films can be also influenced. HA is one of the biodegradable polysaccharides that has been 
broadly studied as a protein carrier. To date, owing to its potential as a drug delivery platform  
HA has been used as carrier for anti-tumoral and anti-inflammatory drugs.
22-25
 Focusing on 
protein delivery, Mero and colleagues developed a HA-aldehyde derivative as an appropriate 
platform for the N-terminal site selective conjugation. To achieve that, short pendant chains of 4-
aminobutyraldehyde were introduced on the HA backbone.
26
 The main advantage of the 
aldehyde moieties attached on the polymeric chain is that under physiological conditions they 
can react with a wide range of amino compounds. Another possible type of oxidized HA is the 
HA derivative with aldehyde groups in position 6 of the N-acetyl-D-glucosamine part.
27, 28
 
Unlike materials prepared by standard oxidation of HA with sodium hypochlorite, this polymer 
consists of intact saccharide rings plausibly mimicking the structure of the native HA 
backbone.
26
 Its capability to react with lysine was also successfully proved
29
 which indicates that 
this polymer is promising for the interaction with polylysine in a multilayer system. Thus, the 
polyelectrolyte multilayer films formed by self crosslinking of PLL and HA-Aldehyde without 
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any addition of elements or stimuli, will constitute an advantage compared to PEMs crosslinked 
with the chemicals like EDC/NHS for example. HA-aldehyde and PLL can interact i) via 
formation of ionic pairs where the cations are the protonated amino groups of PLL and the 
anions are the carboxylic groups of HA, and ii) via formation of a covalent imine bond –CH=N- 
between aldehyde moities of HA and amine groups of polylysine. HA-aldehyde and PLL 
interactions (ionic and covalent) are summarized in Scheme 1. 
 
Scheme 1. Covalent and ionic interactions of PLL and HA-aldehyde chains in a layer-by-layer 
deposited film. The upper chain corresponds to PLL and the lower chain corresponds to HA-
aldehyde. An ionic bond between NH3
+
 moiety from PLL and COO
-
 moiety from HA
- 
is shown 
(red rectangle) and a covalent imine bond resulting from the spontaneous reaction of the 
aldehyde group of HA with an amine group of PLL is drawn (blue rectangle). 
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Frequently, adverse immune reactions against the implanted materials take place in the host 
body, which could compromise an orderly tissue repair. Indirect inflammatory responses can be 
induced by implants in the long term, leading to detrimental effects and damage to the 
surrounding tissues.
30
 One of the key components of inflammation and subsequent events are 
macrophages. They are cells with considerable phenotypic plasticity which are generally 
described within two extreme conditions. The pro-inflammatory M1 macrophage is associated 
with classic signs of inflammation whereas, the pro-healing M2 macrophage stimulates tissue 
repair, immunoregulation and tissue remodeling.
31
 In wound healing process, at early stages a 
pro-inflammatory M1 phenotype is dominant, whereas in  later stages this is shifted towards  a 
pro-healing M2 phenotype. It is known that M1 phenotype macrophages initiate angiogenesis, 
whereas M2 macrophages stabilizes the growing vasculature. The success or failure of a material 
device is strongly dependent on the inflammatory response.
31-33
 Thus, surface coatings which can 
provide long term release of M2 inducing cytokines would help in the resolution of inflammation 
around the implanted materials and can contribute to the faster healing and implant integration 
(more details can be found in the Supporting Information).  
The Layer-by-Layer technique is a well-known method to obtain bioactive coatings with 
multiple functionalities.
34
 The obtained multilayers are widely used as controlled-release drug 
systems without changing their biological function within the coating.
35-38
 Sukhishvili et al. have 
recently reported a coating with a “self-defense” behavior that promotes the release of different 
dose of antibiotic in function of the decrease of the pH around the surface due to the presence of 
bacteria.
39
 Here, we report, for the first time, polyelectrolyte multilayers films made of poly-(L-
lysine) and hyaluroanan-aldehyde (PLL/HA-Ald) derivative, which possess the main advantage 
to form stable structures through an auto-crosslinking mechanism. Their physicochemical 
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properties could enable the release of M2-promoting cytokines such as interleukin-4 (IL-4), to 
promote differentiation of incomming macrophages in the M2 phenotype (anti-inflammatory and 
remodeling promotion) (Scheme 2). 
 
 
Scheme 2. Macrophage differentiation into M2 type is promoted by the implant surface and 
presence of IL-4 release system. 
 
1. Experimental Section 
Synthesis of HA-aldehyde. 
For the preparation of 1 g of HA-aldehyde (sodium formyl hyaluronate or sodium 6(GlcNAc)-
oxo hyaluronate) 1.1 g of sodium hyaluronate (436 kDa, ContiPro) is dissolved in 100 mL of 
demineralized water containing 5 equivalents of disodium hydrogen phosphate (Lach-Ner Ltd, 
Czech Republic). It was added 0.01 equivalent of the catalyst (TEMPO) and the mixture was 
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stirred. The following step was the addition of 0.5 equivalent of sodium hypochlorite at 5
o
C 
(Scheme 3). The reaction solution was then stirred for 2h at this temperature. The final product 
was isolated by dialysis (cut off 12 kDa) against demineralized water and by freeze-drying 
procedure. 
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Scheme 3. Synthesis of HA-Aldehyde derivative verified by 
1
H NMR (D2O) (Supporting 
Information Figure S1).  
 
Production of PLL/HA multilayers 
(PLL, Mw = 52 k Da) was obtained from Alamanda Polymers (Huntsville, USA). Hyaluronic 
acid (HA, 300 kDa) and HA-Aldehyde (HA-Ald, 436 kDa) were produced and characterized as 
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described in the literature.
27-29
 HA-aldehyde derivative is crosslinked to PLL through 
hydrolytically labile imine bonds between amino groups of PLL and aldehydic derivative of HA. 
Polyelectrolyte solutions were prepared in 0.15 M NaCl/10mM Tris buffer at a concentration 
of 0.5 mg.mL
-1
. Multilayer film build up was prepared with a dipping robot (Riegler & Kirstein 
GmbH, Berlin, Germany) on glass slides (12 mm in diameter). The first layer was Poly(L-lysine) 
and after each dipping step of 8 minutes the film was washed in rinsing buffer for 5 min (0.15 M 
NaCl/10mM Tris buffer). The polyanions hyaluronic acids (HA or HA-Ald) were deposited in 
the same way. The build-up process was continued until 24 bilayers of PLL and HA (or HA-Ald) 
were formed.  
Monitoring of the build-up process by quartz crystal microbalance (QCM) 
The build-up process of the multilayer were examined in situ by a QCM (Q-Sense 401 flow 
module QCM-D E1, Q-Sense, Västra Frölunda, Sweden). The molecule adsorption induces the 
quartz crystal, changing the resonance frequency f of it. The quartz crystal was excited at its 
fundamental frequency of 5 MHz and its third harmonic frequency (denoted by ν = 3) at 15 MHz 
was monitored. During each step of molecule adsorption the changes in the resonance frequency, 
(f) were obtained. The crystal used for these experiments is coated with a SiO2 film (100 nm 
thick - QSX 303 crystal from Q-Sense). In first approximation,  the diminution of the normalized 
frequency shift, -f/ν, is be related with a growth of the adsorbed mass on the crystal.40 
Determination of film thickness  
The thickness of the films were obtained by confocal laser analysis. For that, it was used a 
Zeiss confocal microscope (LSM, 710) using a 40x (Zeiss Achroplan) objective. Polyelectrolyte 
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films were labeled by deposition of a FITC (fluorescein-5-isothiocynanate) labelled PLL (PLL-
FITC, Mw = 3.89×10
2
 Da, Sigma Aldrich, France) on top of the film. After excitation, FITC 
fluorescence was detected by argon laser with a cut-off dichroic mirror of 488 nm and emission 
band-pass filter 493-556 nm (green emission). Virtual vertical sections (x,z) can be obtained, 
therefore allowing approximate thickness of the film.
41
 
Determination of molecular mobility by FRAP (Fluorescence Recovery After 
Photobleaching) experiments 
The mobility of PLL-FITC and polyelectrolyte chains within the films was qualitatively 
determined by the FRAP experiments. Briefly, a circular area of 50 µm
2
 of the image (256x256 
pixels) was bleached with the laser set at its maximum power. Then, the disappearance of the 
bleached area and the eventual recovery of the fluorescence were observed at various time 
periods. The rate of recovery of fluorescence in the bleached area is an indirect measurement of 
the mobility of the fluorescence molecule, i.e. PLL-FITC chains.
10
 
Release kinetics of Bovine Serum Albumin (BSA) from the films 
Release experiments of fluorescently labelled BSA (BSA-FITC) were carried out with a 
SAFAS Genius XC spectrofluorimeter (Monaco). PLL/HA films were incubated with BSA-
FITC solution (1 mg.mL
-1
) for 1 hour and then rinsed 3 times with PBS during 5 minutes. The 
release experiments were performed in PBS solution and the data were monitored every 5 
minutes during 24 hours. The measurement parameters were ex/em = 495nm/520nm. 
Before monitoring the release, the quantification of BSA-FITC loaded on the films was done 
by confocal analysis. The method consisted in using a calibration curve by plotting the 
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fluorescence intensities of BSA-FITC solutions (image sections) as a function of their known 
concentrations. Then, fluorescence intensities of the image sections of the loaded film were 
measured and thanks to the calibration curve the concentration of BSA-FITC was determined.
42
 
Release kinetics of IL-4 from the films 
The levels of cytokines were measured with ELISA Development Kits. Standard curves were 
constructed with the included standard protein in phosphate buffer. Samples were analysed 
according to the manufacturer’s protocol. Absorbance was measured at 450 nm with SpectraMax 
Paradigm. Cytokine concentrations were calculated from the best fit line constructed from the 
standard sample dilutions’ OD values plotted against their concentrations. Cytokine 
concentrations were calculated from two parallels of one sample. OD cutoff represents the 
background OD value which corresponds to a standard concentration of 0 ng/mL on the best fit 
line. Minimal detection limit corresponds to the minimal cytokine concentration that can be 
detected with the used ELISA Development Kit according to the manufacturer. 
AFM nanoindentation for elastic modulus analysis 
AFM experiments were done with a MFP3D-BIO instrument (Asylum Research Technology, 
Atomic Force F & E GmbH, Mannheim, Germany). The Young's modulus is calculated by the 
nanoindentation method. The spring constants of the cantilevers measured, using a thermal noise 
method, were found to be 60 pN/nm. Triangular cantilevers with colloidal probe (borosilicate 
glass sphere with a radius of 10 µm, with approach speed of 10 µm/s) were purchased from 
Novascan (Novascan Technologies, Inc. Iowa State University Research Park, IA 50010 USA). 
The experiments were done at room temperature in saline buffer solution at pH 7.4. A grid map 
of 32-by-32 force curves was recorded at different locations of the film surface for obtaining the 
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mechanical properties. 15 nN were the maximal loading force. Elasticity maps were calculated 
based on Dimitriadis model: 
43
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where δ is the indentation depth, ν the Poisson coefficient, R is the colloids radius and h the 
sample thickness. The Dimitriadis correction for finite thickness is defined by χ parameter: 
h
R
 
 
All the curves were analyzed by mean of an automatic Matlab algorithm described 
elsewhere.
44
 
Contrary to the classical Hertz model, Dimitradis model was used in order to take into account 
the mechanical contribution of both the finite thickness of the soft polyelectrolyte film and the 
influence of the supporting hard substrate (glass). Furthermore, Dimitriadis model described the 
mechanical behavior of a finite elastic sample under sphere/plane contact. Such geometrical 
configuration is more relevant than the Hertzian description of paraboloid/plane contact.
43
 
Primary monocyte culture on PLL coating films 
Buffy coats were obtained from the National Blood Service (U.K.) following Ethics committee 
approval. Peripheral blood mononuclear cells (PBMCs) were obtained from heparinised blood by 
Histopaque-1077 (Sigma-Aldrich) density gradient centrifugation. Monocytes were isolated from 
PBMCs using the MACS magnetic cell separation system (positive selection with CD14 
MicroBeads and LS columns, Miltenyi Biotec) as we have previously described.
45
 This method 
[1] 
[2] 
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routinely yielded 95% pure monocytes as determined by flow cytometric analysis of CD14 
expression.  
Purified monocytes were cultured at 1 x 10
6
 cells / mL / well in RPMI-1640 supplemented 
with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U.mL
-1
 penicillin, and 100 µg.mL
-1
 
streptomycin (all from Sigma-Aldrich) in 12-well tissue culture-treated plates containing the 
coated films. Samples and controls were incubated at 37°C, 5% CO2 for 1, 3 and 6 days. Scheme 
4 shows the time line of the experiments and the readouts made. 
Monocytes
seeded on films 
and TC controls
Day 0 Day 6Day 3Day 1
Phase contrast images
alamarBlue assay
Live/Dead staining
Phase contrast images
alamarBlue assay
M1/M2 marker staining
Cytokine analysis
Phase contrast images
alamarBlue assay
Cytokine analysis
 
Scheme 4. Time line of human primary monocyte culture on PLL/HA-Ald films and controls.  
Phase contrast microscopy 
Phase contrast images were captured using an Olympus CDX41 microscope (Olympus 
Corporation, Japan) with an Infinity 2 camera and Infinity Analyze software. 
Blue assay 
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The AlamarBlue assay kit (Thermo Fisher Scientific, USA) was used to determine the cell 
viability as per the manufacturer’s instructions. Controls were monocytes plated in 12-well tissue 
culture-treated plates in the same medium in the absence of any cytokines (TC control). 
Cytokine analysis 
Supernatants were collected and assayed for the cytokines TNF-α, IL-12, IL-1β, CCL18 and 
IL-1RA by ELISA as per the manufacturer’s instructions (Table 1). 
 
Table 1. ELISA kits and standard/sample dilutions 
Cytokine ELISA Kit supplier 
IL-4 PeproTech 900-K14 
IL-1β 
Antibody Solutions AS56-P, AS57-B 
(Capture and detection antibodies) 
Peprotech 200-01B (Standard protein) 
IL-1RA PeproTech 900-K474 
IL-12 PeproTech 900-K96 
CCL18 R&D Systems DY394 
TNFα Peprotech 900-K25 
 
 
 
2. Results and Discussion  
2.1.  PLL/HA and PLL/HA-Aldehyde polyelectrolyte multilayer film characterizations 
The build-up process of the multilayered films was monitored in situ by quartz crystal 
microbalance-dissipation. In first approximation, decreases in the normalized resonance 
frequency -f/ν can be associated with a variation of the mass adsorbed on the crystal. The 
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evolution of -f/ν with the number of deposited layers are exponential for both PLL/HA and 
PLL/HA-Ald, (Figure 1). However in the case of covalent multilayers, the mass adsorbed for a 
given number of layers appears slightly higher than for non-covalent multilayers. Many 
parameters could be at the origin of the difference in these growth like molecular weight of HA 
(300 kDa for HA and 436 kDa for HA-Ald) or the covalent binding of HA-Ald to PLL. 
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Figure 1. Buildup at pH 7.4 /150 mM NaCl of (PLL/HA)6 and (PLL/HA-Ald)6 multilayer films 
on a SiO2-coated crystal followed by QCM-D, evolution of normalized frequency -f/ν  
Section images of (PLL/HA)24/PLL-FITC/HA and (PLL/HA-Ald)24/PLL-FITC/HA-Ald 
multilayer deposited on glass slides are presented in Figure 2. Confocal section images depict for 
both films a homogeneous of PLL-FITC distribution throughout more than 4 µm which probably 
corresponds to the entire film thickness as it was stated previously for non-crosslinked films.
46
 
This may be attributed to the diffusion of mobile PLL-FITC chains in and out of the film due to 
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interlayer mixing of HA and PLL-FITC. This also suggests that despite formation of covalent 
bonding due to the presence of HA-Ald in (PLL/HA-Ald)24 multilayers, some PLL-FITC chains 
are able to diffuse at least during the build up process. 
 
Figure 2. Section images, obtained by confocal laser scanning microscope, of multilayer films 
deposited on glass slides: (a) (PLL/HA)24/PLL-FITC/HA and (b) (PLL/HA-Ald)24/PLL-
FITC/HA-Ald. 
Nanoindentation measurements were then performed with AFM to determine the mechanical 
properties of both films. It is observed that PLL/HA-Ald film is more rigid than PLL/HA, with 
statistically significant difference in Young Moduli of 142 ± 63 kPa for PLL/HA-Ald and 10 ± 4 
kPa for PLL/HA (P<0.001). This strongly indicates the crosslink of HA-Aldehyde chains 
through the reaction of hydrolytically labile imine bond between aldehydic derivative of HA and 
amino groups of PLL chains (Scheme 1). Increase in the Young modulus could be advantageous 
for biological applications where hard substrates are generally better for cell proliferation. 
Then, FRAP experiments (fluorescence recovery after photobleaching) were performed and 
showed that after bleaching a circular area in the PLL/HA film, the green fluorescence 
corresponding to PLL-FITC chains was almost (80%) totally recovered after 50 minutes (Figure 
3). This found recovery was due to lateral mobility of the PLL chains within the film. It was 
previously demonstrated that about 70% of PLL chains are mobile in a non-cross-linked 
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PLL/HA film.
47
 In comparison, when PLL/HA-Ald was used, the recovery of fluorescence was 
slower. This indicates that mobility of PLL-FITC in PLL/HA-Ald is lower than that on PLL/HA, 
and it could suggest that some PLL-FITC chains are crosslinked and could not diffuse any more. 
From Figure 3, we can conclude that almost 40% of the fluorescence is recovered in PLL/HA-
Ald and thus about 60% of PLL chains are immobile. Finally FRAP experiments confirm that 
HA-Ald is able to crosslink the film. In comparison with the more conventional method using 
EDC, HA-Ald is a self-crosslinking method that do not need any additional steps with chemicals 
after the film buildup. 
PLL/HA films are known to have the capacity to be loaded with a high amount of proteins like 
Human Serum Albumin 
42
 or drugs like paclitaxel.
48
 However little is known on this aspect for 
covalent multilayers and nothing is known for HA-Ald. In order to study the release behavior of 
our multilayer films, the FITC-labeled bovine serum albumin (BSA-FITC) and interleukin 4 (IL-
4) were loaded on the top of the films. BSA is used as a model protein and IL-4 is the cytokine 
selected for our immunomodulation studies described later. BSA-FITC (100 µL) was deposited 
for 1h at a concentration of 1 mg.mL
-1
 on top of either PLL/HA or PLL/HA-Ald films. After 
rinsing steps, it was observed by confocal analysis that there is no difference in amounts of BSA-
FITC adsorbed on PLL/HA or on PLL/HA-Ald films, in each case the concentration of BSA in 
the film was 35 mg.mL
-1
 of BSA-FITC (see Supplementary Information Figure S2 for calibration 
curve), which corresponds to 14 µg of BSA loaded per cm
2
 on each film. This suggests that both 
film can be loaded with a high amount of BSA greater than the solution concentration (1mg.mL
-
1
) and finally they act as a kind of "sponge" for proteins. This renders such coatings of high 
interest to functionalize biomedical devices.  
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Release kinetics of BSA out of multilayer films in presence of PBS was investigated by 
fluorimetry. The release profiles seem to be dependent on the film crosslinking, the release of 
BSA-FITC from PLL/HA-Ald is slower for the first 24 hours than for non-crosslinked PLL/HA 
films (Figure 4a). This constitutes an interesting property as effectiveness of the PLL/HA film to 
release a protein can probably be tuned by playing with the crosslinking degree (HA/HA-Ald 
ratio for example) and moreover long-term release can probably be reached with PLL/HA-Ald 
films. The BSA-FITC release kinetics was also monitored in presence of medium containing 
serum, to mimic the concentration of proteins present in blood/interstitial fluid in vivo 
(Supplementary Information Figure S3). For non-crosslinked PLL/HA films, the release of BSA-
FITC is almost similar when PBS or media containing serum have been used as supernantant : 
0.08 mg.mL
-1
 is released after 24h in both cases. However for crosslinked PLL/HA-Ald films the 
amount of BSA-FITC released after 24h is about 3 times higher in complete medium compared 
to PBS. Finally the slower release and thus the higher affinity of BSA to PLL/HA-Ald films can 
be attributed to higher hydrophobicity in these films because covalent PLL/HA interaction could 
be more tight and could release more water.  
Then we focused our study on the release of interleukin 4 (IL-4), a key cytokine in type 2 
immunity, which is also essential for anti-helminth protection, wound healing, and allergy.
49
 This 
protein with a molecular weight of 15 kDa is positively charged at pH 7.4 (pI=9.17). From QCM 
experiments, we monitored a loading rate of IL-4 corresponding to an increase of normalized 
frequency value of about 75 Hz for (PLL/HA)6 and (PLL/HA-Ald)6 films (data not shown), 
which means that the same adsorbed amount of the cytokines was adsorbed for both films. 
Unlike BSA, IL-4 released at the first 48 hours is significantly higher for PLL/HA-Ald films 
compared to PLL/HA films (t-test, P ≤0.042, n=3), (Figure 4b). Finally this means that PLL/HA-
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Ald films have better mechanical property than PLL/HA films due to the crosslinking however 
they maintain the same ability to release IL-4.  
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Figure 3. Fluorescence recovery in a (PLL/HA)24-PLL-FITC-HA (HA) and in a (PLL/HA-
Ald)24-PLL-FITC-HA-Ald (Ald) after photobleaching as a function of time after bleaching. 
 20 
 
Figure 4. Kinetic of biomolecules release from PLL/HA and PLL/HA-Ald in presence of PBS: 
(a) BSA-FTIC and (b) IL-4. 
3.2  Monocyte phenotype and behavior on PLL/HA and PLL/HA-Ald multilayers 
In order to determine, whether the release of IL-4 can control macrophage phenotype on 
PLL/HA films, primary monocytes were seeded on the films in the presence and absence of IL-4. 
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On day 3 monocytes seeded on PLL/HA and PLL/HA-Ald films with or without IL-4, appeared 
similar in size and morphology (Figure 5a). On day 6 monocytes on PLL/HA in presence or 
absence of IL-4 remained small and spherical, whereas monocytes on PLL/HA-Ald appeared 
larger and some adherent cells were observed on the PLL/HA-Ald films, in particular on IL-4 
loaded films (Figure 5b). 
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Figure 5. Phase contrast images of monocytes seeded on the films after (a) 3 and (b) 6 days of 
culture on PLL/HA and PLL/HA-Aldehyde in presence or not of IL-4. Scale bar = 100 µm. 
The metabolic activity of the cells was evaluated and it was shown to be time-dependent for all 
conditions (Figure 6). On day 1 and 6, there was no apparent difference in viability among 
PLL/HA and PLL/HA-Ald groups with or without IL-4. Cells seeded on PLL/HA-Ald show the 
highest viability on day 3, with the highest value compare to PLL/HA and PLL/HA-Ald groups 
(Figure 6). 
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Figure 6. Metabolic activity of monocytes seeded on PLL/HA and PLL/HA-Ald with or without 
IL-4 after 1, 3 and 6 days (AlamarBlue assay). Controls were monocytes plated in well tissue 
culture-treated plates in the same medium in the absence of any cytokines (TC control, 100%). 
The cells seeded on PLL/HA without IL-4 produced high levels of pro-inflammatory cytokines 
(TNF-α, IL-12, and IL-β). This shows that the monocytes are easily activated to pro-
inflammatory macrophages due to the surface. However, the level of pro-inflammatory cytokines 
TNF-α was strongly reduced at day 3 and day 6 on PLL/HA-Ald films even in absence of IL-4 
(Figure 7 a, b). Moreover, addition of IL-4 on PLL/HA films also strongly reduced TNF-α 
production compare to non-functionalized PLL/HA. Production of IL-12, a second 
proinflammatory cytokine, was quite high at day 3 on PLL/HA or PLL/HA-Ald. However 
adding IL-4 reduced the production (Figure 7c). At day 6, a similar effect was observed for 
PLL/HA films (Figure 7d). Also, IL-4 functionalized films strongly reduced the level of the 
proinflammatory IL-1β at day 3 or day 6 (Figure 7 e, f). Finally, these results suggest that the 
crosslinking of PLL/HA films inhibit the differentiation of macrophage phenotype into a pro-
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inflammatory (M1 type). Moreover, adding IL-4 in the films also limit the pro-inflammatory 
macrophages. 
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Figure 7. Pro-inflammatory cytokines produced from monocytes seeded on PLL/HA, PLL/HA-
Ald with or without IL-4: TNF-α after 3 (a) and 6 days (b); IL-12 after 3 (c) and 6 days (d), IL-
1β after 3 (e) and 6 days (f). 
Regarding anti-inflammatory cytokine production, monocytes seeded on PLL/HA and 
PLL/HA-Ald produced IL-1RA. However, the presence of IL-4 increased the amount at day 3 
for PLL/HA and PLL/HA-Ald and at day 6 for PLL/HA (Figure 8a, b). In the case of PLL/HA-
Ald, IL-1RA production on day 6 was similar in the presence or absence of IL-4 (Figure 8b). On 
the contrary, CCL18 production by cells on PLL/HA films occurred only in presence of IL-4 
(Figure 8c, d). Once again, cells on PLL/HA-Ald films produced CCL18 in the absence of IL-4 
(on day 3 or 6), but production was higher when the films had been loaded with IL-4, (Figure 8c, 
d). These results with anti-inflammatory cytokines mainly confirm those obtain with the pro-
inflammatory, i.e. both crosslinking of the film and addition of cytokines IL-4 drive the 
differentiation into M2 macrophages over M1 macrophages.  
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Figure 8. Anti-inflammatory cytokines produced from monocytes seeded on PLL/HA, PLL/HA-
Ald with or without IL-4: IL-1RA after 3 (a) and 6 days (b), CCL18 after 3 (c) and 6 days (d). 
Finally, PLL/HA-Ald films could have applications where anti-inflammatory / pro-wound 
healing macrophage populations would be beneficial in improving the rate and quality of implant 
integration, protection of biomedical devices such as electrodes from adverse immune reactions. 
 
Conclusions 
In summary, the results show that polyelectrolyte multilayers made of PLL and HA-aldehyde 
derivative can be successfully built. The introduction of the bioactive molecules, interleukin-4, 
can be used for functionalization these films. Moreover, drug release behavior could be 
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modulated by tuning the physical property of the films, such as Young Modulus. The main 
objective of this study is to use the controlled release capacities of the PLL/HA films for the 
delivery of immunomodulatory cytokines such as IL-4. PLL/HA-Aldehyde films stimulate the 
anti-inflammatory response on monocytes even in the absence of IL-4. However IL-4 improves 
in an efficient way the anti-inflammatory properties of the coating. The designed film could be 
applied in the future to medical devices like implants to trigger differentiation of monocytes in a 
pro-healing phenotype. Such coatings can be used in the control of initial inflammatory reactions 
to permanent titanium implants such as dental, orthopaedic replacement systems or in 
neuroprosthetic devices in the brain. We plan to use these coatings also for improvement of 
integration of recently developed artificial larynx system that is clinical trial stage. 
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